Full Results of PEARL IV Study Presented at the European Society of Gynaecological Endoscopy (ESGE) Congress Confirms the Efficacy of Ulipristal Acetate 5 mg for the Long Term Management of Uterine Fibroids

BUDAPEST, Hungary, October 9, 2015 /PRNewswire/ --

Gedeon Richter Plc. ("Richter") announces results of the PEARL IV study at ESGE. PEARL IV was a Phase III, randomized, double-blind, parallel group study investigating the efficacy and safety of repeated 3 months treatment courses of daily 5mg or 10mg[a] ulipristal acetate (UPA) for the long-term management of symptomatic uterine fibroids, characterized by heavy bleeding.[1] The study, which investigated 4 treatment courses in patients across 46 European centres in 11 countries, showed:

- Approximately 93%[b] of women or greater achieved controlled bleeding at the end
of each treatment course and at least 76%[c] of women were in amenorrhoea[d] at the
end of each treatment courses
- There was a 67% median reduction in fibroid volume at the end of treatment course 4[e]
- 65.5%, 73.5%, 74.7% and 78.1% of patients had clinically significant reduction of the
three largest fibroids (i.e. greater than or equal to 25% reduction) after each
consecutive treatment course[f] with UPA 5mg (4 courses in total)
- 73.5% of women experienced both amenorrhea and clinically significant fibroid
reduction (greater than or equal to 25%) with 4 repeated courses
- The use of ulipristal acetate showed an improvement in quality of life (QoL) and pain
which was maintained during the off treatment intervals
- The safety profile for UPA in this trial confirmed the previously reported safety
profile. The vast majority of AEs (97.6%) were of mild or moderate severity in both
- Hot flushes and headaches were the most frequently reported adverse reactions. (pooled
5 and 10 mg: Headache, less than or equal to 4.4% for any treatment course; hot flush,
less than or equal to 5.8 % any treatment course)[g]

     (Logo: http://photos.prnewswire.com/prnh/20151007/275089LOGO )

"The PEARL IV data show that ulipristal acetate 5mg is an effective and well-tolerated treatment for the long-term management of uterine fibroids." said Erik Bogsch, Managing Director of Gedeon Richter Plc. "At Gedeon Richter we are committed to women's health and developing products that will enhance their quality of life and safeguard their fertility."

"Unfortunately, uterine fibroids can have a serious impact on the physical and emotional wellbeing of women, and this has been made worse by the limited options that have been available to them in the past. I welcome the findings of all the PEARL studies, and particularly the PEARL IV study, demonstrating that ulipristal acetate 5mg is a well-tolerated and effective long term option for the management of uterine fibroids," said Prof. Jacques Donnez, lead investigator in PEARL I and II and lead author of the NEJM articles.

"Women that have been diagnosed with uterine fibroids in the past often felt bewildered due to the lack of options available to them, especially when faced with extreme options such as a hysterectomy", said Deborah Lancastle, Health Psychologist at the University of Wales, United Kingdom. "Providing women with a variety of treatment options, including a long-term management option that doesn't involve surgery, will be a relief."  

The initial Marketing Authorization for UPA 5mg was granted in 2012 for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The new indication allowing intermittent medical treatment of the moderate to severe symptoms of uterine fibroids with UPA 5mg, was granted in May 2015[h] and provides an important opportunity for many women suffering from this condition to potentially avoid surgical interventions.

The PEARL IV study confirmed the efficacy and safety of repeated intermittent use of UPA, and the final results also confirmed already published data from previous Phase III studies (PEARL III and its extension[2] and PEARL IV Part 1[3]).

The full UPA 5mg tablets product information containing the revised SmPC is publicly available both in the registers of the European Commission / European Medicines Agency and of the National Institute of Pharmacy and Nutrition Register in Hungary together with their respective online sites: http://www.ema.europa.eu and http://www.ogyei.gov.hu .

About uterine fibroids [http://www.preglem.com/product-portfolio/uterine-fibroids ]

About Esmya(R) (ulipristal acetate) [http://www.preglem.com/product-portfolio/uterine-fibroids ]

About Richter [https://www.richter.hu/en-US/about-us/Pages/Ceo-s-message.aspx ]

a. Please note that the 10mg dose is not licensed 
b. Data from per protocol 4 (PP4) population, where subjects had started and received
at least 56 days of medication in the 4th treatment course 
c. Data from PP4 population 
d. Defined as no more than 1 day of spotting within a 35-day interval 
e. Data from PP4 population 
f. Data from PP4 population, based on data recorded after each treatment course plus 1
g. Data from PEARL IV safety population 
h. Esmya 5 mg tablets are indicated for pre-operative and intermittent treatment of
moderate to severe symptoms of uterine fibroids in women of reproductive age



[1] Donnez J, et al. Fertil Steril "in-press" 
[2] Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids
with ulipristal acetate. Fertil Steril 2014;101(6):1565-73. 
[3] Donnez, J; Hudecek, R; Donnez, O. et al. Efficacy and Safety of repeated use of
ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103(2):519-27



For further information:  

Katalin Ordog 

Zsuzsa Beke 



Gedeon Richter Plc.

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234